Company Encyclopedia
View More
name
YABAO PHARM.CORP
600351.SH
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Beijing, China.
3.157 T
600351.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking150/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.75%B
    • Profit Margin9.80%B
    • Gross Margin53.41%B
  • Growth ScoreD
    • Revenue YoY-19.73%E
    • Net Profit YoY0.97%C
    • Total Assets YoY-9.49%E
    • Net Assets YoY-7.63%D
  • Cash ScoreC
    • Cash Flow Margin1020.08%B
    • OCF YoY-19.73%E
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreA
    • Gearing Ratio17.52%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    YABAO PHARM.CORP: Cumulatively spent 52.1519 million yuan to repurchase 1.14% of shares

    YABAO PHARM.CORP announced that the company will repurchase shares through centralized bidding starting from May 16, 2025, with an expected amount of 50 million to 100 million yuan, aimed at reducing registered capital. As of October 31, a total of 8 million shares have been repurchased, accounting for 1.14% of the total share capital, with a total payment of 52.1519 million yuan, and the repurchase price range is 6.30 yuan/share to 6.65 yuan/share. The company will implement the repurchase at an opportune time during the repurchase period and disclose progress in a timely manner

    Zhitong·
    SH
    600351
    -0.15%
    Zhitong·
    SH
    600351
    -0.15%

    YABAO PHARM.CORP released its performance for the first three quarters, with a net profit attributable to the parent company of 215 million yuan, a year-on-year decrease of 8.44%

    According to the Zhitong Finance APP, YABAO PHARM.CORP disclosed its third-quarter report for 2025. The company achieved revenue of 1.709 billion yuan in the first three quarters, a year-on-year decrease of 19.46%; the net profit attributable to the parent company was 215 million yuan, a year-on-year decrease of 8.44%; the net profit excluding non-recurring gains and losses was 197 million yuan, a year-on-year decrease of 9.03%; and the basic earnings per share were 0.3066 yuan

    Zhitong·
    SH
    600351
    -0.15%
    Zhitong·
    SH
    600351
    -0.15%

    YABAO PHARM.CORP: Sitagliptin Metformin Extended-Release Tablets have obtained the drug registration certificate

    YABAO PHARM.CORP announced that its wholly-owned subsidiary Beijing YABAO Biopharmaceutical Co., Ltd. has obtained the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets issued by the National Medical Products Administration. This medication is suitable for adult patients with type 2 diabetes, used in combination with Sitagliptin and Metformin. Sitagliptin Metformin Extended-Release Tablets were developed by MERCK SHARP DOHME and were approved for sale in the United States in 2012 under the brand name JANUMETXR®. It is expected that the sales of this drug in the domestic market will reach 921 million yuan in 2024

    Zhitong·
    SH
    600351
    -0.15%
    Zhitong·
    SH
    600351
    -0.15%

    YABAO PHARM.CORP disclosed the progress of its share repurchase, having repurchased a total of 6 million shares

    YABAO PHARM.CORP disclosed the progress of its share repurchase. Since the shareholders' meeting approved the repurchase proposal on May 16, 2025, the company has repurchased a total of 6 million shares, accounting for 0.86% of the total share capital. The repurchase period is from May 16, 2025, to November 14, 2025, with an expected repurchase amount between 50 million and 100 million yuan, mainly used to reduce registered capital. The highest transaction price for the repurchase was 6.65 yuan/share, the lowest was 6.30 yuan/share, and the total payment amount was 38,878,040 yuan

    Zhitong·
    SH
    600351
    -0.15%
    Zhitong·
    SH
    600351
    -0.15%

    YABAO PHARM.CORP's controlling shareholder repurchased 13.65 million pledged shares in advance

    YABAO PHARM.CORP's controlling shareholder, YABAO Investment, repurchased 13.65 million pledged shares in advance on September 26. After the pledge is lifted, the total pledged shares amount to 24.95 million, accounting for 26.46% of its holdings. YABAO Investment holds 94.3 million shares of the company, representing 13.47% of the total share capital. The company will closely monitor the pledge matters and disclose information in a timely manner

    Zhitong·
    SH
    600351
    -0.15%
    Zhitong·
    SH
    600351
    -0.15%
    © 2025 Longbridge｜Disclaimer